ArticleOncogene2019
Stepwise detection and evaluation reveal miR-10b and miR-222 as a remarkable prognostic pair for glioblastoma.
Article in Oncogene, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 43 citations in OpenAlex.
- Investigating glioblastoma chemoresistance: a meta-analysis of microRNA signatures and gene networks.Journal of neuro-oncology · 2025Pooled it
- Prognostic Role of MicroRNA 222 in Patients with Glioma: A Meta-analysis.BioMed research international · 2020Pooled it
- Human umbilical cord mesenchymal stem cells derived exosomes enhance the therapeutic efficacy of anti-miR-10b in glioblastoma.Scientific reports · 2026Article
- Review
- Nanotherapy Targeting miR-10b Improves Survival in Orthotopic Glioblastoma Models.Journal of functional biomaterials · 2025Article
- Lipid nanoparticle formulation for gene editing and RNA-based therapies for glioblastoma.Neuro-oncology · 2025Article
- i-Motif DNA molecular beacon for microRNA detection.Nucleic acids research · 2025Article
- The Clinical Role of miRNAs in the Development and Treatment of Glioblastoma.International journal of molecular sciences · 2025Review
- Unraveling the mechanisms of glioblastoma's resistance: investigating the influence of tumor suppressor p53 and non-coding RNAs.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Circulating biomarkers for diagnosis and response to therapies in cancer patients.International review of cell and molecular biology · 2025Review
- Review
- Secreted PGK1 and IGFBP2 contribute to the bystander effect of miR-10b gene editing in glioma.Molecular therapy. Nucleic acids · 2023Article
- Co-administration of temozolomide (TMZ) and the experimental therapeutic targeting miR-10b, profoundly affects the tumorigenic phenotype of human glioblastoma cells.Frontiers in molecular biosciences · 2023Article
- Small Non-Coding RNAs in Human Cancer.Genes · 2022Review
- Synergistic Effects of A Combined Treatment of Glioblastoma U251 Cells with An Anti-miR-10b-5p Molecule and An AntiCancer Agent Based on 1-(3',4',5'-Trimethoxyphenyl)-2-Aryl-1International journal of molecular sciences · 2022Article
- Sox2 induces glioblastoma cell stemness and tumor propagation by repressing TET2 and deregulating 5hmC and 5mC DNA modifications.Signal transduction and targeted therapy · 2022Article
- Mesenchymal stem cell-derived exosomes as new tools for delivery of miRNAs in the treatment of cancer.Frontiers in bioengineering and biotechnology · 2022Review
- lncRNA TUG1 as a ceRNA promotes PM exposure-induced airway hyper-reactivity.Journal of hazardous materials · 2021Article
- Article
- Prognostic Value of microRNA-221/2 and 17-92 Families in Primary Glioblastoma Patients Treated with Postoperative Radiotherapy.International journal of molecular sciences · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the existence of many clinical and molecular factors reported that contribute to survival in glioblastoma, prevailing studies fell into partial or local feature selection for survival analysis. We proposed a feature selection strategy including not only joint covariate detection but also its evaluations, and performed it on miRNA expression profiles with glioblastoma. MiR-10b and miR-222 were selected as the most significant two-dimensional feature. Crucially, we integrated in vitro experiments on GBM cells and in vivo studies on a mouse model of human glioma to elucidate the synergistic effects between miR-10b and miR-222. Inhibition of miR-10b and miR-222 strongly suppress GBM cells growth, invasion, and induce apoptosis by co-targeting PTEN and leading to activation of p53 ultimately. We also demonstrated that miR-10b and miR-222 co-target BIM to induce apoptosis independent of p53 status. The results define mir-10b and mir-222 important roles in gliomagenesis and provided a reliable survival analysis strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.